TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group, Inc.

Transmedics develops and offers medical technology products that focus on organ transplantation, specifically through the Organ Care System.

msh id	COM:TRANSMEDICS
symbol	TMDX
name	TransMedics Group, Inc.
homepage url	https://www.transmedics.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	584
crunchbase url	-
linkedin url	-
founders	-

market cap	4.56B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.93
growth cost of revenue	2.11
growth depreciation and amortization	9.26
growth ebitda	1.27
growth ebitda ratio	1.1
growth eps	-
growth eps diluted	-
growth general and administrative expenses	1.31
growth gross profit	1.36
growth gross profit ratio	-0.09

COM:TRANSMEDICS

Transmedics

Last Close

77.20

21/11 21:00

Market Cap

4.56B

Beta: -

Volume Today

1.50M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	241.14M
cost of revenue	241.14M
depreciation and amortization	8.28M
ebitda	8.76M
ebitda ratio	0.04
eps	-0.77
eps diluted	-0.77
operating expenses	153.51M
operating income	485K
operating income ratio	0

accounts receivables	-33.82M
capital expenditure	-179.06M
cash at beginning of period	201.18M
cash at end of period	394.81M
inventory	44.24M
working capital ttm	487.62M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-